Histone Acetylation and Disease
Annick Harel‐Bellan, Institut Andre Lwoff, Villejuif, France
Valentina Guasconi, Institut Andre Lwoff, Villejuif, France
Lauriane Fritsch, Institut Andre Lwoff, Villejuif, France
Redha Sekhri, Institut Andre Lwoff, Villejuif, France
Heike Lehrmann, Institut Andre Lwoff, Villejuif, France
Slimane Ait‐Si‐Ali, Institut Andre Lwoff, Villejuif, France
Published online: January 2006
DOI: 10.1038/npg.els.0006032
Abstract
Acetylation of nucleosomal core histones plays a key regulatory role in many physiological processes such as proliferation
and differentiation. Aberrant acetylation or deacetylation of histones leads to severe human diseases such as leukemia, epithelial
cancers, fragile X‐syndrome and Rubinstein–Taybi syndrome.
Keywords: histone acetyltransferase; histone deacetylase; histone, chromatin; leukemia
References
Ait‐Si‐Ali S,
Polesskaya A,
Filleur S, et al.
(2000)
CBP/p300 histone acetyl‐transferase activity is important for the G1/S transition.
Oncogene
19(20): 2430–2437.
Jenuwein T and
Allis CD
(2001)
Translating the histone code.
Science
293(5532): 1074–1080.
Magnaghi‐Jaulin L,
Ait‐Si‐Ali S and
Harel‐Bellan A
(2000)
Histone acetylation and the control of the cell cycle.
Progress in Cell Cycle Research
4: 41–47.
Marmorstein R and
Roth SY
(2001)
Histone acetyltransferases: function, structure, and catalysis.
Current Opinion in Genetics and Development
11(2): 155–61.
Narlikar GJ,
Fan HY and
Kingston RE
(2002)
Cooperation between complexes that regulate chromatin structure and transcription.
Cell
108(4): 475–487.
Timmermann S,
Lehrmann H,
Polesskaya A, et al.
(2001)
Histone acetylation and disease.
Cellular and Molecular Life Sciences: CMLS
58(5,6): 728–736.
Torchia J,
Glass C and
Rosenfeld MG
(1998)
Co‐activators and co‐repressors in the integration of transcriptional responses.
Current Opinion in Cellular Biology
10(3): 373–383.
Web Links
CREBBP, (CREB binding protein (Rubinstein–Taybi syndrome)); Locus ID: 1387. LocusLink:
http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=1387
FMR1 (fragile X mental retardation 1); Locus ID: 2332. LocusLink:
http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=2332
MECP2 (methyl CpG binding protein 2 (Rett syndrome)); Locus ID: 4204. LocusLink:
http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=4204
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4); Locus ID: 6597. LocusLink:
http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=6597
TP53 (tumor protein p53 (Li–Fraumeni syndrome)); Locus ID: 7157. LocusLink:
http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=7157
CREBBP (CREB binding protein (Rubinstein–Taybi syndrome)); MIM number: 600140. OMIM:
http://www.ncbi.nlm.nih.gov/htbin‐post/Omim/dispmim?600140
FMR1 (fragile X mental retardation 1); MIM number: 309550. OMIM:
http://www.ncbi.nlm.nih.gov/htbin‐post/Omim/dispmim?309550
MECP2 (methyl CpG binding protein 2 (Rett syndrome)); MIM number: 300005. OMIM:
http://www.ncbi.nlm.nih.gov/htbin‐post/Omim/dispmim?300005
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4); MIM number: 603254. OMIM:
http://www.ncbi.nlm.nih.gov/htbin‐post/Omim/dispmim?603254
TP53 (tumor protein p53 (Li–Fraumeni syndrome)); MIM number: 191170. OMIM:
http://www.ncbi.nlm.nih.gov/htbin‐post/Omim/dispmim?191170